Bosentan-induced immune hemolytic anemia in 17 years old man. A case report.

Fatemeh Afra, Marjan Mehri, Soha Namazi
{"title":"Bosentan-induced immune hemolytic anemia in 17 years old man. A case report.","authors":"Fatemeh Afra,&nbsp;Marjan Mehri,&nbsp;Soha Namazi","doi":"10.1007/s40199-020-00386-1","DOIUrl":null,"url":null,"abstract":"<p><p>Hemolytic anemia is a very important immune-mediated reaction, which its late diagnosis can be fatal. Medications along with other causes can induce hemolytic anemia. Drug induced immune hemolytic anemia (DIIHA) is caused by the development of autoantibodies. Accordingly, DIIHA is rare and there is not enough data for its prevalence. Number of drugs that can cause DIIHA have increased in recent decades. A 17-year-old man who had congenital single ventricle heart (CHB) and pulmonary artery hypertension (PAH) was admitted at Imam Khomeini hospital complex affiliated to Tehran University of Medical Sciences, with chief complaint of jaundice and icter. Bosentan and Tadalafil were in the list of the drugs used by this patient. Although both drugs were recommended to be discontinued in the patient, in the course of hospitalization, the patient accidentally continued to take his Tadalafil. However, the patient's recovery continued. Given that the patient's Coombs test was positive, his hemolytic anemia mechanism was drug-induced immune-mediated hemolytic anemia. As a result, according to Naranjo score = 6, Bosentan was considered as the main possible culprit to induce DIIHA in this patient. Following the discontinuation of Bosentan and receiving Prednisolone, the patient's clinical symptoms and laboratory parameters resolved and the patient was then discharged.</p>","PeriodicalId":10961,"journal":{"name":"Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences","volume":"29 1","pages":"211-215"},"PeriodicalIF":0.0000,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s40199-020-00386-1","citationCount":"7","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s40199-020-00386-1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/24 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 7

Abstract

Hemolytic anemia is a very important immune-mediated reaction, which its late diagnosis can be fatal. Medications along with other causes can induce hemolytic anemia. Drug induced immune hemolytic anemia (DIIHA) is caused by the development of autoantibodies. Accordingly, DIIHA is rare and there is not enough data for its prevalence. Number of drugs that can cause DIIHA have increased in recent decades. A 17-year-old man who had congenital single ventricle heart (CHB) and pulmonary artery hypertension (PAH) was admitted at Imam Khomeini hospital complex affiliated to Tehran University of Medical Sciences, with chief complaint of jaundice and icter. Bosentan and Tadalafil were in the list of the drugs used by this patient. Although both drugs were recommended to be discontinued in the patient, in the course of hospitalization, the patient accidentally continued to take his Tadalafil. However, the patient's recovery continued. Given that the patient's Coombs test was positive, his hemolytic anemia mechanism was drug-induced immune-mediated hemolytic anemia. As a result, according to Naranjo score = 6, Bosentan was considered as the main possible culprit to induce DIIHA in this patient. Following the discontinuation of Bosentan and receiving Prednisolone, the patient's clinical symptoms and laboratory parameters resolved and the patient was then discharged.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
波生坦致17岁男性免疫性溶血性贫血一份病例报告。
溶血性贫血是一种非常重要的免疫介导反应,其晚期诊断可能是致命的。药物和其他原因可引起溶血性贫血。药物性免疫性溶血性贫血(DIIHA)是由自身抗体的产生引起的。因此,DIIHA是罕见的,没有足够的数据表明其流行程度。近几十年来,可引起DIIHA的药物数量有所增加。一名患有先天性单心室心脏(CHB)和肺动脉高压(PAH)的17岁男子被德黑兰医科大学附属伊玛目霍梅尼医院收治,主因为黄疸和心绞痛。波生坦和他达拉非在该患者使用的药物清单中。虽然这两种药物都建议患者停用,但在住院期间,患者意外地继续服用他达拉非。然而,病人的康复仍在继续。考虑到患者Coombs试验阳性,其溶血性贫血机制为药物性免疫介导的溶血性贫血。因此,根据Naranjo评分= 6,Bosentan被认为是诱发该患者DIIHA的可能罪魁祸首。在停用波生坦并接受泼尼松龙治疗后,患者的临床症状和实验室参数得到缓解,然后出院。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Correction: Flavonoid as possible therapeutic targets against COVID-19: a scoping review of in silico studies. A rare case of phenobarbital-induced leukocytoclastic vasculitis. Deciphering the similarities and disparities of molecular mechanisms behind respiratory epithelium response to HCoV-229E and SARS-CoV-2 and drug repurposing, a systems biology approach. Simulation of drug-drug interactions between breast cancer chemotherapeutic agents and antiemetic drugs. The use of therapeutic drug monitoring to highlight an over-looked drug-drug interaction leading to imatinib treatment failure.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1